Table 2.
NPC risk, according to a combined measure of anti-EBNA1 IgA and anti-gp350 antibodies
| Total (N) | Incident Case (N) | Disease-free Control (N) | Odds Ratio (95% CI) | |
|---|---|---|---|---|
| EBNA1 IgA negativea | 29 | 3 | 26 | 1.00 (Referent) |
| EBNA1 IgA positive | 41 | 17 | 24 | 6.1 (1.6–23.6) |
| Elevated anti-gp350b | 6 | 1 | 5 | 1.7 (0.15–20.2) |
| Not elevated anti-gp350 | 35 | 16 | 19 | 7.3 (1.9–28.7) |
a
Seropositivity for EBNA1 IgA defined as previously defined(11)
b
Elevated anti-gp350 antibody level defined as upper median of the anti-gp350 distribution in participants.